
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report: October 21, 2022

(Commission File No. 001-39308)

CALLIDITAS THERAPEUTICS AB

(Translation of registrant's name into English)

Kungsbron 1, D5

SE-111 22

Stockholm, Sweden

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Enclosed hereto is a copy of an announcement published by Calliditas Therapeutics AB on October 21, 2022.

The information contained in this Form 6-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

EXHIBIT INDEX

Exhibit	Description
<u>99.1</u>	<u>Press Release dated October 21, 2022</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CALLIDITAS THERAPEUTICS AB

Date: October 21, 2022

By: /s/ Fredrik Johansson
Fredrik Johansson
Chief Financial Officer



Stockholm, Sweden

October 21, 2022

Calliditas Therapeutics' nomination committee composition for the AGM 2023

Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2023.

The nomination committee, which is appointed in accordance with the principles adopted by the extraordinary general meeting in 2017, consists of:

- Patrick Sobocki, appointed by Stiftelsen Industrifonden
- Karl Tobieson, appointed by Linc AB
- Jan Särilvik, appointed by Fjärde AP-fonden
- Elmar Schnee (chairman of the board of directors)

The nomination committee shall, before the annual general meeting 2023, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, election of auditors, the determination of fees and matters pertaining thereto.

For more information please visit:

<https://www.calliditas.se/en/nomination-committee-2314/>

Shareholders who wish to submit proposals to the nomination committee for the annual general meeting on May 17, 2023, can do so by e-mail to finance@calliditas.com. Proposals should be submitted to the nomination committee before March 29, 2023.

For further information, please contact:

Fredrik Johansson, CFO at Calliditas
Email: fredrik.johansson@calliditas.com
Telephone: +46 703 52 91 90

The information was submitted for publication, through the agency of the contact person set out above, at 10.00 a.m CET on October 21, 2022.

About Calliditas Therapeutics

Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYOTM and conditional marketing authorization by the European Commission under the trade name KINPEYGO®. KINPEYGO is being commercialized in the European Union Member States by Calliditas' partner, STADA Arzneimittel AG. Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
